tert-butyl N-(1-benzoylpiperidin-4-yl)carbamate | 429677-00-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl N-(1-benzoylpiperidin-4-yl)carbamate
• 英文别名: tert-butyl (1-benzoylpiperidin-4-yl)carbamate；tert-Butyl 1-benzoylpiperidin-4-ylcarbamate
• CAS: 429677-00-9
• 化学式: C₁₇H₂₄N₂O₃
• mdl: MFCD01763531
• 分子量: 304.389
• InChiKey: QNEKFNMBKJEMEJ-UHFFFAOYSA-N

物化性质

• 沸点：
  461.1±34.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.529
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl N-(1-benzoylpiperidin-4-yl)carbamate 在 potassium hydride 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 [4-(甲基氨基)哌啶-1-基]-苯基甲酮
  参考文献：
  名称：

  Nonpeptide Inhibitors of Cathepsin G:  Optimization of a Novel β-Ketophosphonic Acid Lead by Structure-Based Drug Design

  摘要：

  The serine protease cathepsin G (EC 3.4.21.20; Cat G), which is stored in the azurophilic granules of neutrophils (polymorphonuclear leukocytes) and released on degranulation, has been implicated in various pathological conditions associated with inflammation. By employing high-throughput screening, we identified beta-ketophosphonic acid 1 as a moderate inhibitor of Cat G (IC(50) = 4.1 microM). We were fortunate to obtain a cocrystal of 1 with Cat G and solve its structure by X-ray crystallography (3.5 A). Structural details from the X-ray analysis of 1.Cat G served as a platform for optimization of this lead compound by structure-based drug design. With the aid of molecular modeling, substituents were attached to the 3-position of the 2-naphthyl ring of 1, which occupies the S1 pocket of Cat G, to provide an extension into the hydrophobic S3 region. Thus, we arrived at analogue 7 with an 80-fold potency improvement over 1 (IC(50) = 53 nM). From these results, it is evident that the beta-ketophosphonic acid unit can form the basis for a novel class of serine protease inhibitors.

  DOI：

  10.1021/ja017506h
• 作为产物：
  描述：

  苯甲酰氯 在 三甲基氯硅烷 、 三乙胺 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 25.0h， 生成 tert-butyl N-(1-benzoylpiperidin-4-yl)carbamate
  参考文献：
  名称：

  一类稳定酰胺在可见光照射下通过自芳构化作为酰基转移试剂

  摘要：

  合成了一种新型稳定的酰胺，在光照射下可以与酰氯等各种亲核试剂发生反应。这种可控的开启反应性取决于合理设计的光激活掩蔽酰基供体试剂。

  DOI：

  10.1002/chem.202401619

文献信息

• [EN] INHIBITORS OF BACTERIAL GLYCOSYL TRANSFERASES<br/>[FR] INHIBITEURS DE GLYCOSYL TRANSFÉRASES BACTÉRIENNES
  申请人：HARVARD COLLEGE

  公开号：WO2016191658A1

  公开（公告）日：2016-12-01

  Described herein are compounds of Formula (I'), Formula (IA), Formulae (I)-(VII), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrug sthereof. The invention also provides pharmaceutical compositions of the compounds for human and veterinary use. Compounds of the present invention are useful for inhibiting bacterial growth and therefore are useful in treating and/or preventing bacterial infections. Methods of using the compounds for treating and/or preventing a bacterial infection in a subject are also described.

  本文描述了式(I')、式(IA)、式(I)-(VII)的化合物，以及这些化合物的药用盐、溶剂合物、水合物、多型体、共晶体、互变异构体、立体异构体、同位素标记衍生物和前药。本发明还提供了这些化合物的用于人类和兽医用途的药物组合物。本发明的化合物对抑制细菌生长有用，因此在治疗和/或预防细菌感染方面具有用途。还描述了使用这些化合物治疗和/或预防受试者细菌感染的方法。
• [EN] ATYPICAL INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF<br/>[FR] INHIBITEURS ATYPIQUES DE TRANSPORTEURS DE MONOAMINE ; LEUR PROCÉDÉ DE PRODUCTION ET D'UTILISATION
  申请人：US HEALTH

  公开号：WO2019094856A1

  公开（公告）日：2019-05-16

  Disclosed herein are a series of modafinil analogue compounds that bind with moderate to high affinity to the dopamine (DA) transporter (DAT) and several analogues also having affinity for the serotonin (5-HT) transporter (SERT) and/or sigma-1 receptor. Employing aminopiperidine, piperidineamino, spirobicyclodiaza, or substituted piperazine functional groups, desired dopamine transporter affinity has been retained along with improved metabolic stability over unsubstituted piperazine ring analogues. Importantly, these compounds have no predicted addictive liability. Also disclosed are methods for treating substance use disorders as well as other neuropsychiatric disorders such as ADHD, depression, narcolepsy, and cognitive impairment.

  本发明公开了一系列莫达非尼类似物化合物，这些化合物以中等至高亲和力结合多巴胺（DA）转运体（DAT），并且其中几种类似物还对血清素（5-HT）转运体（SERT）和/或σ-1受体具有亲和力。通过使用氨基哌啶、哌啶氨基、螺二氮杂环或取代的哌嗪功能团，不仅保留了对多巴胺转运体的亲和力，而且相对于未取代的哌嗪环类似物，其代谢稳定性得到了改善。重要的是，这些化合物没有预测到的成瘾性。此外，还公开了治疗物质使用障碍以及其他神经精神障碍如注意力缺陷多动障碍（ADHD）、抑郁症、嗜睡症和认知损害的方法。
• Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability
  作者：JoLynn B. Giancola、Alessandro Bonifazi、Jianjing Cao、Therese Ku、Alexandra J. Haraczy、Jenny Lam、Rana Rais、Mark A. Coggiano、Gianluigi Tanda、Amy Hauck Newman

  DOI：10.1016/j.ejmech.2020.112674

  日期：2020.12

  psychostimulant abuse. However, metabolic instability among other limitations to piperazine analogues 1–3 have impeded further development. Herein, bioisosteric substitutions of the piperazine ring were explored with a series of aminopiperidines (A) and piperidine amines (B) wherein compounds with either a terminal tertiary amine or amide were synthesized. Several lead compounds showed high to moderate DAT

  尽管在开发治疗精神兴奋剂使用障碍的药物方面付出了相当大的努力，但没有一种药物被证明是有效的，这使得患者群体服务不足，并且关于开发药物疗法应该针对什么作用机制的问题也没有得到解答。基于 (±) 莫达非尼的非典型多巴胺转运蛋白 (DAT) 抑制剂已在精神兴奋剂滥用的临床前模型中显示出治疗潜力。然而，代谢不稳定以及哌嗪类似物的其他局限性1-3阻碍了进一步的发展。在本文中，用一系列氨基哌啶 (A) 和哌啶胺 (B) 探索了哌嗪环的生物等排取代，其中合成了具有末端叔胺或酰胺的化合物。几种先导化合物在大鼠肝微粒体中显示出高至中等的 DAT 亲和力和代谢稳定性。 与可卡因相比，氨基哌啶7 (DAT K i  = 50.6 nM)、21b (DAT K i  = 77.2 nM) 和33 (DAT K i = 30.0 nM) 仅对小鼠的行走活动产生最小的刺激，表明非典型的 DAT 抑制剂谱.
• QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20150239844A1

  公开（公告）日：2015-08-27

  The present invention is directed to quinoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders.

  本发明涉及喹啉衍生物，含有该衍生物的药物组合物以及它们在治疗由CB-1受体介导的疾病和症状中的用途；更具体地，在对CB-1受体的反向激动作用反应的疾病和症状的治疗中。例如，本发明的化合物在治疗代谢性疾病方面是有用的。
• [EN] PYRAZINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS<br/>[FR] COMPOSÉS PYRAZINES POUR LE TRAITEMENT DE TROUBLES APPARENTÉS À GPR119
  申请人：BIOVITRUM AB PUBL

  公开号：WO2009106561A1

  公开（公告）日：2009-09-03

  The application relates to compounds of Formula (Ia), and pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers and N-oxides thereof. The application also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the prophylaxis and treatment of medical conditions relating to disorders of the G-protein-coupled receptor GPRl 19, such as diabetes, obesity and osteoporosis.

  该申请涉及到化合物(Ia)的公式，以及其药学上可接受的盐、溶剂化合物、水合物、几何异构体、互变异构体、光学异构体和N-氧化物。该申请还涉及包含这些化合物的药物组合物，以及利用这些化合物预防和治疗与G蛋白偶联受体GPRl 19的疾病相关的医疗状况，如糖尿病、肥胖和骨质疏松症。